Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 4,137 JPY | +0.12% | -1.43% | +0.63% | |
| Sales 2024 * | 4,007B 27.22B | Sales 2025 * | 3,924B 26.65B | Capitalization | 6,483B 44.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 147B 999M | Net income 2025 * | 245B 1.67B | EV / Sales 2024 * | 2,54x |
| Net Debt 2024 * | 3,714B 25.23B | Net Debt 2025 * | 3,344B 22.72B | EV / Sales 2025 * | 2,50x |
| P/E ratio 2024 * | 49,0x | P/E ratio 2025 * | 27,5x | Employees | 49,095 |
| Yield 2024 * | 4,55% | Yield 2025 * | 4,58% | Free-Float | 98.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.94% | ||
| 1 week | -1.69% | ||
| Current month | -0.79% | ||
| 1 month | -0.43% | ||
| 3 months | -8.38% | ||
| 6 months | -7.52% | ||
| Current year | +0.51% |
1 week
4 119.00
4 206.00
1 month
4 098.004 245.00
Current year
3 981.004 873.00
1 year
3 917.004 873.00
3 years
2 993.004 873.00
5 years
2 894.504 873.00
10 years
2 894.506 693.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 2014 |
| Director of Finance/CFO | 52 | 2014 | |
Mwana Lugogo
CMP | Compliance Officer | 53 | 2011 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 2016 | |
Ian Clark
BRD | Director/Board Member | 62 | 2018 |
Steven Gillis
BRD | Director/Board Member | 70 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 24.44% | 7 M€ | +2.39% | ||
| 7.75% | 2 M€ | +16.58% | - | |
| 5.00% | 231 M€ | +31.34% | ||
| 4.15% | 104 M€ | -15.42% | ||
| 4.12% | 3 M€ | -16.65% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 4,137 | +0.12% | 2 893 000 |
| 23-12-04 | 4,132 | -0.94% | 3,015,400 |
| 23-12-01 | 4,171 | +0.14% | 3,364,400 |
| 23-11-30 | 4,165 | +0.85% | 5,667,000 |
| 23-11-29 | 4,130 | -1.60% | 3,795,500 |
Delayed Quote Japan Exchange, December 04, 2023 at 01:00 am EST
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
4,132JPY
Average target price
4,724.74JPY
Spread / Average Target
+14.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.51% | 44 448 M $ | |
| +60.09% | 525 B $ | |
| +47.59% | 454 B $ | |
| -10.06% | 381 B $ | |
| -5.31% | 262 B $ | |
| -10.80% | 253 B $ | |
| -15.22% | 221 B $ | |
| +3.05% | 202 B $ | |
| -8.49% | 200 B $ | |
| -42.86% | 163 B $ |
